Top in rheumatology: Arthritis in people with ACL ruptures; benefits of frequent exercise

Researchers reported that many younger patients with an ACL rupture developed knee osteoarthritis within 5 years of their injury.

According to Elanna K. Arhos, PT, DPT, PhD, of the University of Delaware, and colleagues, “post-traumatic osteoarthritis in the knee joint is one of many concerning long-term outcomes facing individuals who have torn their ACL.” It was the top story in rheumatology last week.

Another top story was about health-related improvements among patients with knee and hip osteoarthritis who frequently exercised.

Read these and more top stories in rheumatology below:

Osteoarthritis prevalence ‘highly concerning’ in younger patients with ACL rupture

The prevalence of osteoarthritis among younger patients with ACL rupture is “highly concerning,” with 30% of the youngest cohort — at a median age of 22 years — having involved knee osteoarthritis within 5 years of their injury, according to researchers. Read more.

Patients with knee, hip OA who exercise frequently demonstrate improved long-term function

Patients with hip or knee osteoarthritis who report frequent physical activity demonstrate improved health-related quality of life and physical function over a period of 5 years, according to data published in Arthritis Care & Research. Read more.

Anifrolumab increases odds of earlier, sustained low disease activity vs placebo in lupus

Patients with systemic lupus erythematosus receiving anifrolumab are more likely to achieve earlier, more frequent and longer low disease activity, compared with those taking placebo, according to data. Read more.

Guselkumab’s safety profile consistent regardless TNF-inhibitor use in psoriatic arthritis

The 2-year safety profile of guselkumab appears consistently favorable across patients with psoriatic arthritis who are either naïve or experienced with TNF inhibitors, according to data published by The Journal of Rheumatology. Read more.

One-quarter of patients with axial SpA remain flare-free after ceasing etanercept

In patients with non-radiographic axial spondyloarthritis who achieved inactive disease with etanercept, approximately 25% remained flare-free at 40 weeks after ceasing treatment, according to data published in the Journal of Rheumatology. Read more.